Indefinite Delivery Contract 75D30123D15815
Award Date
12/31/22
Last Date to Order
2/28/24
Federal Agency
CDC Pittsburgh
Awardee
Seqirus USA Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to provide pediatric flu vaccines for 2023-2024. Astrazeneca Pharmaceuticals LP is the prime contractor for this multiple-award contract with a potential value of $58.53M. The contract aims to procure pediatric flu vaccines through a series of task orders against an established price list. As the lead federal agency for public health emergency...
The Centers for Disease Control and Prevention awarded a single award indefinite delivery contract to Seqirus USA Inc. with a potential value of $180,705,000. The contract aims to procure pediatric influenza vaccines for children ages 0 through 18 years old to support immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. Task orders will be issued against the contract to purchase required vaccines each flu season through February 28,...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to provide pediatric flu vaccines for the 2020-2021 season. The contract has a potential value of $140.25 million and was awarded to Glaxosmithkline, LLC on January 7, 2020, with an ordering period through February 28, 2021. The original solicitation sought proposals to supply between 60-80 million doses of pediatric flu vaccines for nationwide delivery....
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Seqirus USA Inc., through its Seqirus USA, Inc. division, for the procurement of pediatric influenza vaccines. The contract has a ceiling value of $208,520,000 and a performance period through February 28, 2023. Under this IDC, Seqirus will provide between 100 doses to 50 million doses of pediatric influenza vaccines, in various presentations and National Drug Codes, to support...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Seqirus USA Inc. for adult flu vaccines for 2023-2024. The potential value of the contract is $146,103,060. Orders may be placed through February 28, 2024. The contract aims to procure adult flu vaccines to support the CDC's efforts in disease prevention. As the leading public health agency in the United States, the CDC works to control and prevent...
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in the development, manufacturing, and delivery of influenza vaccines. The $318,010,000 IDC, with a period of performance from January 2, 2024 to February 28, 2025, is for the procurement of pediatric flu vaccines to support the CDC's annual vaccination program. Seqirus, through its Seqirus USA,...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $410,587,500 multiple-award IDC covers the procurement of 2025-2026 pediatric flu vaccines for the federal government. As a registered federal contractor since 2008, Seqirus USA Inc. has extensive experience supplying influenza vaccines to various government...